The Bet Behind BASF's Rally

If you only glanced at BASF headlines, the Zhanjiang Verbund project promising €4 billion to €5 billion in annual sales by 2030 might have looked like a distant story, not a near term share price catalyst. Investors who held BASF over the past year are up 30.3%, including dividends. If you were deciding back in October 2025, what did you need to believe about this capital-heavy China bet and the wider portfolio reshuffle to be comfortable buying?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

BASF has already moved. Pinpoint other ways to investigate the theme among 33 best rare earth metal stocks.

The Two BASF Stories Investors Had To Price In

The shares cost €43.02 at the start of the period, and BASF investors were weighing two very different stories about what that price already assumed.

The bullish narrative set a fair value of €49.92, 16% above the start price. It focused on BASF pushing ahead with portfolio streamlining, including divesting lower-growth units and preparing an Agricultural Solutions IPO by 2027. It also reflected the view that cost savings and the Zhanjiang Verbund buildout could support improvements in net margins.

The bearish view anchored to a fair value of €39. It treated rising decarbonization and environmental compliance costs as a core threat to BASF, and argued that tougher regulation could shrink demand for traditional chemicals and plastics and make long-term margin improvement difficult to achieve.

What The BASF Evidence Actually Tested

The Zhanjiang Verbund site starting operations on schedule and below budget, with a plan to use 100% renewable power, supported the BASF narrative that large China capital expenditure and decarbonization spending could still support margins. Quarterly figures pointed the other way on profitability, since revenue and profit rose while net margin slipped from 1.0% to 0.9%. The evidence cut both ways.

The key assumption here was margin resilience during heavy investment. When you assess another stock with a large project and cost program, track not just revenue and earnings but also whether the reported net margin holds or improves as those projects move from promise to operation.

What BASF's One Year Run Already Prices In

BASF now trades at €53.46, after a 30.3% gain over the past year. The selected Narrative’s Fair Value sits below the current price and frames today’s level as already baking in meaningful execution on cash generation and portfolio reshaping.

For a buyer today, the working assumption is that higher earnings will convert into solid free cash flow and lower net debt. The selected Narrative examines how ongoing working capital build, transformation costs and any large deal risk might affect that outcome.

"Despite BASF reporting higher EBITDA before special items and raising its 2026 EBITDA guidance range, free cash flow in Q2 2026 moved to a loss of €189m with working capital build and about €200m of transformation cash outflows. This points to a risk that ongoing cost programs and earnings guidance do not translate into the expected improvement in free cash flow and net debt reduction."

One Narrative disagrees with today's price. → See where this Narrative says BASF should trade

Find Your Own Contrarian Opportunity

You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.

• Company 1 - 39% below our estimate - refocuses on core fan communities while sequencing major content and product launches.
• Company 2 - 41% below our estimate - deepens use of precision treatment software as providers modernize oncology planning and workflows.
• Company 3 - 34% below our estimate - extends subscription-led recommerce ecosystem while driving efficiency gains across fulfillment operations.

That is three of the list. See all 204 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com